Clinical Trial Update: Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1 [Phase 2]

View source ↗

Summary

This update reports the completion and results posting of a Phase 2 trial evaluating encaleret in Autosomal Dominant Hypocalcemia Type 1, focusing on safety, to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Hypocalcemia
• Autosomal Dominant Hypocalcemia Type

Drugs mentioned

• Encaleret (encaleret)

Snippet

Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company | Conditions: Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Phase 2 | Status: COMPLETED | Results posted: 2024-11-19